<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Angela MC Rose</style></author><author><style face="normal" font="default" size="100%">Nathalie Nicolay</style></author><author><style face="normal" font="default" size="100%">Virginia Sandonis Martín</style></author><author><style face="normal" font="default" size="100%">Clara Mazagatos</style></author><author><style face="normal" font="default" size="100%">Petrović, Goranka</style></author><author><style face="normal" font="default" size="100%">Joaquin Baruch</style></author><author><style face="normal" font="default" size="100%">Sarah Denayer</style></author><author><style face="normal" font="default" size="100%">Lucie Seyler</style></author><author><style face="normal" font="default" size="100%">Domegan, Lisa</style></author><author><style face="normal" font="default" size="100%">Odile Launay</style></author><author><style face="normal" font="default" size="100%">Ausenda Machado</style></author><author><style face="normal" font="default" size="100%">Cristina Burgui</style></author><author><style face="normal" font="default" size="100%">Roberta Vaikutyte</style></author><author><style face="normal" font="default" size="100%">Annabel F Niessen</style></author><author><style face="normal" font="default" size="100%">Isabela I Loghin</style></author><author><style face="normal" font="default" size="100%">Petr Husa</style></author><author><style face="normal" font="default" size="100%">Nassera Aouali</style></author><author><style face="normal" font="default" size="100%">George Panagiotakopoulos</style></author><author><style face="normal" font="default" size="100%">Kristin Tolksdorf</style></author><author><style face="normal" font="default" size="100%">Judit Krisztina Horváth</style></author><author><style face="normal" font="default" size="100%">Jennifer Howard</style></author><author><style face="normal" font="default" size="100%">Francisco Pozo</style></author><author><style face="normal" font="default" size="100%">Gallardo, Virtudes</style></author><author><style face="normal" font="default" size="100%">Diana Nonković</style></author><author><style face="normal" font="default" size="100%">Aušra Džiugytė</style></author><author><style face="normal" font="default" size="100%">Nathalie Bossuyt</style></author><author><style face="normal" font="default" size="100%">Thomas Demuyser</style></author><author><style face="normal" font="default" size="100%">Róisín Duffy</style></author><author><style face="normal" font="default" size="100%">Liem binh Luong Nguyen</style></author><author><style face="normal" font="default" size="100%">Irina Kislaya</style></author><author><style face="normal" font="default" size="100%">Iván Martínez-Baz</style></author><author><style face="normal" font="default" size="100%">Giedre Gefenaite</style></author><author><style face="normal" font="default" size="100%">Mirjam J Knol</style></author><author><style face="normal" font="default" size="100%">Corneliu Popescu</style></author><author><style face="normal" font="default" size="100%">Lenka Součková</style></author><author><style face="normal" font="default" size="100%">Marc Simon</style></author><author><style face="normal" font="default" size="100%">Stella Michelaki</style></author><author><style face="normal" font="default" size="100%">Janine Reiche</style></author><author><style face="normal" font="default" size="100%">Annamária Ferenczi</style></author><author><style face="normal" font="default" size="100%">Concepción Delgado-Sanz</style></author><author><style face="normal" font="default" size="100%">Zvjezdana Lovrić Makarić</style></author><author><style face="normal" font="default" size="100%">John Paul Cauchi</style></author><author><style face="normal" font="default" size="100%">Cyril Barbezange</style></author><author><style face="normal" font="default" size="100%">Els van Nedervelde</style></author><author><style face="normal" font="default" size="100%">O'Donnell, Joan</style></author><author><style face="normal" font="default" size="100%">Christine Durier</style></author><author><style face="normal" font="default" size="100%">Raquel Guiomar</style></author><author><style face="normal" font="default" size="100%">Jesús Castilla</style></author><author><style face="normal" font="default" size="100%">Indrė Jonikaite</style></author><author><style face="normal" font="default" size="100%">Patricia CJL Bruijning-Verhagen</style></author><author><style face="normal" font="default" size="100%">Mihaela Lazar</style></author><author><style face="normal" font="default" size="100%">Regina Demlová</style></author><author><style face="normal" font="default" size="100%">Gil Wirtz</style></author><author><style face="normal" font="default" size="100%">Marina Amerali</style></author><author><style face="normal" font="default" size="100%">Ralf Dürrwald</style></author><author><style face="normal" font="default" size="100%">Mihály Pál Kunstár</style></author><author><style face="normal" font="default" size="100%">Kissling, Esther</style></author><author><style face="normal" font="default" size="100%">Sabrina Bacci</style></author><author><style face="normal" font="default" size="100%">Marta Valenciano</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">I-MOVE-COVID-19 hospital study team</style></author><author><style face="normal" font="default" size="100%">VEBIS hospital study team</style></author><author><style face="normal" font="default" size="100%">Members of the I-MOVE-COVID-19 and VEBIS hospital study teams (in addition to authors above)</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022.</style></title><secondary-title><style face="normal" font="default" size="100%">Euro Surveill</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19 Vaccines</style></keyword><keyword><style  face="normal" font="default" size="100%">Europe</style></keyword><keyword><style  face="normal" font="default" size="100%">Hospitalization</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Pneumonia</style></keyword><keyword><style  face="normal" font="default" size="100%">RNA, Messenger</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style  face="normal" font="default" size="100%">Vaccine Efficacy</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2023 Nov</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">28</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;IntroductionThe I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021.AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥ 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period).MethodsIn both networks, 46 hospitals (13 countries) follow a similar test-negative case-control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received ≥ 14 days before symptom onset (stratifying first booster into received &amp;lt; 150 and ≥ 150 days after last PSV dose). We measured VE overall, by vaccine category/product, age group and time since first mRNA booster dose, adjusting by site as a fixed effect, and by swab date, age, sex, and presence/absence of at least one commonly collected chronic condition.ResultsWe included 2,779 cases and 2,362 controls. The VE of all vaccine products combined against hospitalisation for laboratory-confirmed SARS-CoV-2 was 43% (95% CI: 29-54) for complete PSV (with last dose received ≥ 150 days before onset), while it was 59% (95% CI: 51-66) after addition of one booster dose. The VE was 85% (95% CI: 78-89), 70% (95% CI: 61-77) and 36% (95% CI: 17-51) for those with onset 14-59 days, 60-119 days and 120-179 days after booster vaccination, respectively.ConclusionsOur results suggest that, during the Omicron period, observed VE against SARI hospitalisation improved with first mRNA booster dose, particularly for those having symptom onset &amp;lt; 120 days after first booster dose.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">47</style></issue></record></records></xml>